Food Intervention to Reduce Immunotherapy ToXicity

NCT05832606

Status	RECRUITING
Phase	Not Applicable
Sponsor	Universitair Ziekenhuis Brussel
Enrollment	60 participants

Key Eligibility Criteria

Inclusion (2)

- solid tumor starting anti-programmed cell death protein 1 (anti-PD1) and/or anti-cytotoxic T-lymphocyte-associated antigen 4 (anti-CTLA4) antibodies as part of standard of care.
- able to sign informed consent.

Exclusion (3)

- no oral intake possible.
- probiotic use and unwillingness to stop during the trial.
- combination therapy with chemotherapy or targeted agents.

Locations (1 total)

UZ Brussel, Jette, Belgium